Company Overview and News

 
QL pares gains after rising to all-time high

2018-10-03 theedgemarkets
KUALA LUMPUR (Oct 3): QL Resources Bhd shares rose as much as 21 sen or 3% to record high at RM7.08 so far today, after Kenanga Investment Bank Bhd raised its target price (TP) for the egg producer's shares to RM5. At 4:06pm, QL shares pared gains at RM7.02 among Bursa Malaysia top gainers. QL saw 2.57 million shares traded.
7084 BSMAF 1818

 
FBM KLCI notches limited gains as region stays muted

2018-10-01 theedgemarkets
KUALA LUMPUR (Oct 1): The FBM KLCI notched up limited gains at the midday break today as decliners overtook advancers, against the backdrop of mixed regional markets.
APEXF 7084 7090 BATS 4162 0082 1163 5268 5256 6033 5199 0020 5843 0176 PNADF 1201 3301 7108 1899 2836 HIPEF PNAGF

 
FBM KLCI pares gains, subdued in line with region

2018-10-01 theedgemarkets
KUALA LUMPUR (Oct 1): The FBM KLCI pared some of its gains at mid-morning, keeping the local index subdued in line with the regional markets on the first trading day of the fourth quarter.
APEXF 7090 BATS 4162 2089 5256 9334 5199 5008 5843 1201 3026 3301 3867 2836 HIPEF PNAGF 7084 UPBMF 5681 5268 6033 PNADF 0026 1899

 
Subdued start to 4Q for FBM KLCI, tracks region

2018-10-01 theedgemarkets
KUALA LUMPUR (Oct 1): The FBM KLCI got off to a subdued start on the first trading day of the fourt quarter of 2018, tracking regional markets.
7084 5183 PECGF UPBMF 5681 2089 6033 4588 PNADF 5225 1368 Q0F IHHHF PNAGF

 
QL Resources rises to all-time high

2018-09-28 theedgemarkets
KUALA LUMPUR (Sept 28): QL Resources Bhd shares rose as much as 38 sen or 6%, more than any full-day gain since June 4, while Malaysia's benchmark index declined.
7084

 
KLCI claws back to erase loss, Tenaga lifts

2018-09-26 theedgemarkets
KUALA LUMPUR (Sept 26): The FBM KLCI clawed back to erase its earlier losses at the midday break today, powered by gains at Tenaga Nasional Bhd and other select index-linked blue chips.
7084 7060 7036 0083 BATS 4162 7765 1163 5256 9334 5199 0154 KLKBY 5029 2445 5347 5258 3026 7216 TNABY 2836 TNABF HIPEF 1929

 
QL Resources’ fundamentals seen to remain strong

2018-09-25 theedgemarkets
QL Resources Bhd (Sept 24, RM6.34) Maintain neutral with an unchanged target price (TP) of RM4.68: We recently visited one of QL Resources Bhd’s marine product manufacturing (MPM) plants in Hutan Melintang, Perak, operated by its subsidiary, QL Foods Sdn Bhd. The MPM division contributed 27.7% and 48.6% of the group’s revenue and profit before tax (PBT) respectively for the financial year ended March 31, 2018 (FY18), while Hutan Melintang plants contribute more than 30% (around RM300 million) of the MPM division’s revenue and 35% of QL’s overall MPM segment capacity.
7084

 
QL Resources advances to record high

2018-09-21 theedgemarkets
KUALA LUMPUR (Sept 21): QL Resources Bhd shares rose as much as 23 sen or 3.65% to RM6.53, as Malaysia's benchmark index advanced.
7084

 
KLCI up 0.39% in tandem with regional uptrend

2018-09-21 theedgemarkets
KUALA LUMPUR (Sept 21): The FBM KLCI rose 0.39% at midday break Friday, tracking gains at regional markets, as worries over the US-China trade tensions abated somewhat.
7084 7052 GMALF 5681 BATS 4162 5134 7079 GMALY 5139 KLKBY 2445 3301 4715 7216 0900 0026 2836

 
KLCI remains firmly above 1,800-level

2018-09-21 theedgemarkets
KUALA LUMPUR (Sept 21): The FBM KLCI remained firmly above the 1,800-point level at mid-morning and was up 0.37%, tracking the gains at regional markets.
HLFBF 7084 7052 1082 BATS 4162 7374 0089 5139 KLKBY 2445 3301 7216 0900 0026 2836

 
KLCI up 0.41% in tandem with regional gains

2018-09-21 theedgemarkets
KUALA LUMPUR (Sept 21): The FBM KLCI rose 0.41% in early trade this morning, tracking gains at most regional markets, lifted by select index-linked blue chips.
7084 BATS 4162 5014 6033 5139 PNADF 5347 0900 TNABY MYPRY 2836 TNABF PNAGF

 
QL Resources may climb higher, says RHB Retail Research

2018-09-18 theedgemarkets
KUALA LUMPUR (Sept 18): RHB Retail Research said QL Resources Bhd may climb higher after posting a white candle and hitting its new 52-week high.
7084

 
KLCI gains 0.61%, crosses 1,800 level as regional sentiment perks up

2018-09-14 theedgemarkets
KUALA LUMPUR (Sept 14): The FBM KLCI rose 0.61% and crossed the 1,800 level at midday break, in line with gains at regional markets, as sentiment received a boost from expectations of fresh US-China negotations.
7084 BATS 4162 5983 0096 7123 5199 CIMDF 1023 3026 1201 3867 6645 4405 HIPEF

 
QL Resources shares up at highest in 18 years

2018-09-14 theedgemarkets
KUALA LUMPUR (Sept 14): QL Resources Bhd shares rose 3 percent, more than any full-day gain since June 4, as Malaysia's benchmark index advanced.
7084

 
KLCI rises 0.26%, tracks regional markets

2018-09-14 theedgemarkets
KUALA LUMPUR (Sept 14): The FBM KLCI rose 0.26% at mid-morning today, tracking gains at regional markets, lifted by select blue chips.
7084 1023 5258 3026 2836 0096 5256 7199 9334 7123 CIMDF

Related Articles

ALIM: Alimera Sciences Analysis and Research Report

2018-10-01 - Asif

Overview The following discussion and analysis should be read in conjunction with its unaudited interim condensed consolidated financial statements and the related notes that appear elsewhere in this quarterly report on Form 10-Q. This discussion contains forward-looking statements reflecting its current expectations that involve risks and uncertainties. Actual results may differ materially from those discussed in these forward-looking statements due to a number of factors, including those set forth in the section entitled “Risk Factors” in its most recent annual report on Form 10-K. For further information regarding forward-looking statements, please refer to the “Special Note Regarding Forward-Looking Statements and Projections” immediately after the index to this quarterly report on Form 10-Q. Alimera Sciences, Inc., and its subsidiaries (we or Alimera), is a pharmaceutical company that specializes in the commercialization and development of prescription ophthalmic pharma...

DMPI: DelMar Pharmaceuticals Analysis and Research Report

2018-09-25 - Asif

Background DelMar Pharmaceuticals, Inc. is a clinical stage drug development company with a focus on the treatment of cancer. The company's mission is to benefit patients and create shareholder value by developing and commercializing anti-cancer therapies for patients whose tumors exhibit features that make them resistant to, or unlikely to respond to, currently available therapies, particularly for orphan cancer indications where patients have failed, or are unlikely to respond to, currently available therapy. DelMar Pharmaceuticals is developing VAL-083, a novel, DNA-targeting agent, for the treatment of glioblastoma multiforme (“GBM”) and potentially other solid tumors, including ovarian cancer. VAL-083 is a first-in-class, DNA-targeting chemotherapeutic that demonstrated activity against a range of tumor types in prior Phase 1 and Phase 2 clinical studies sponsored by the US National Cancer Institute (“NCI”). The company's recent research has highlighted the opportunit...

RIGL: Rigel Pharmaceuticals Analysis and Research Report

2018-09-18 - Asif

Overview Rigel Pharmaceuticals is a biotechnology company dedicated to discovering, developing and providing novel small molecule drugs that significantly improve the lives of patients with immune and hematologic disorders, cancer and rare diseases. The company's pioneering research focuses on signaling pathways that are critical to disease mechanisms. The company's first FDA-approved product is TAVALISSE™ (fostamatinib disodium hexahydrate), an oral spleen tyrosine kinase (SYK) inhibitor, for the treatment of adult patients with chronic immune thrombocytopenia who have had an insufficient response to a previous treatment. The company's current clinical programs include Phase 2 studies of fostamatinib in autoimmune hemolytic anemia and IgA nephropathy, and a Phase 1 study for its IRAK program. In addition, Rigel Pharmaceuticals has product candidates in development with partners BerGenBio AS, Daiichi Sankyo, and Aclaris Therapeutics. Since inception, Rigel Pharmaceuticals h...